Welcome!

News Feed Item

Researchers Identify Splice Variant of Breast Cancer Gene that Can Mask Risk of Recurrence

'High Risk' Patients with Unusual Hormone Receptors May Be Undertreated

IRVINE, Calif. and AMSTERDAM, Aug. 27, 2013 /PRNewswire/ -- Agendia, a leader in molecular cancer diagnostics, announced today that researchers have identified a subset of breast cancer patients whose standard biomarker tests may incorrectly classify patients as "low risk" and benefitting from endocrine therapy. A study published this month in Breast Cancer Research and Treatment* concluded that this subset of breast cancer patients may actually be at "high risk" of disease progression and benefit more from chemotherapy than endocrine therapy.

The researchers found that 2 percent of breast cancer patients tested, who were identified as estrogen receptor positive (ER+) and therefore potential candidates to benefit from endocrine therapy, actually had a variant of the estrogen receptor called "delta Exon 7 deletion." This variant is missed by standard receptor testing and reported as receptor positive, when in fact the variant protein inhibits the normal estrogen signal in the cell that may prevent the patient from benefitting from routine endocrine therapy. Moreover, these patients have a genomic profile of their tumor that suggests that 95% of these are "at high recurrence risk and would likely benefit from adjuvant chemotherapy," the researchers concluded.

The researchers identified the importance of the delta Exon 7 deletion through a test called BluePrint®, which was developed by Agendia.  BluePrint is one part of a suite of related breast cancer tests called Symphony, which provides a complete view of a patient's prognosis and helps guide their individual treatment decisions through genomic profiling. 

"The researchers identified the presence of the Exon 7 variant of the estrogen receptor while trying to determine why some breast cancer patients who tested ER+ in the classical test for receptor status turned out to be of the 'basal-like' subtype by the BluePrint assay, which indicates a lack of a functional estrogen pathway," noted Stephanie R. Akbari, M.D., Medical Director of the Reinsch Pierce Family Center for Breast Health at Virginia Hospital Center, a member of the research team. "Medical experts have long established that ER+ tumors typically benefit from hormonal therapies, but we also know that not all patients with ER+ tumors benefit from this therapy. This finding may help identify those patients that are unlikely to benefit from hormonal therapy."

Dr. Akbari said, "Our findings show that, as we discover the importance of splicing variants such as Exon7, additional molecular subtyping of a patient's tumor is necessary to reach a more accurate understanding of the disease."

Agendia CEO David Macdonald said, "Agendia's Symphony is the only commercially available test suite that provides molecular subtyping and can identify the growing body of important genetic variants such as Exon 7.  This research underscores Agendia's commitment to ongoing discovery and collaboration between industry and physician-directed research in bringing scientific advances into clinical practice."

About Agendia:

Agendia is a leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products. Agendia's breast cancer Symphony suite was developed by analyzing the complete human genome, ensuring 100% definitive results for cancer patients. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods. MammaPrint®, the initial test in the Symphony suite is the only FDA cleared test which determines recurrence risk in breast cancer patients.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The Company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.  For more information, please visit www.agendia.com.

*Breast Cancer Res. Treat. 140:475–484 (2013).

For further information, please contact:

Allen & Caron Inc.
Matt Clawson or
Len Hall (Financial Media)
949-474-4300
[email protected] 
[email protected]

SOURCE Agendia

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
With so much going on in this space you could be forgiven for thinking you were always working with yesterday’s technologies. So much change, so quickly. What do you do if you have to build a solution from the ground up that is expected to live in the field for at least 5-10 years? This is the challenge we faced when we looked to refresh our existing 10-year-old custom hardware stack to measure the fullness of trash cans and compactors.
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
The emerging Internet of Everything creates tremendous new opportunities for customer engagement and business model innovation. However, enterprises must overcome a number of critical challenges to bring these new solutions to market. In his session at @ThingsExpo, Michael Martin, CTO/CIO at nfrastructure, outlined these key challenges and recommended approaches for overcoming them to achieve speed and agility in the design, development and implementation of Internet of Everything solutions wi...
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed, managed, analyzed, and acted upon by enterprise IT. This amazing is not part of some distant future - it is happening today. One report shows a 650% increase in enterprise data by 2020. Other estimates are even higher....
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportuni...
Identity is in everything and customers are looking to their providers to ensure the security of their identities, transactions and data. With the increased reliance on cloud-based services, service providers must build security and trust into their offerings, adding value to customers and improving the user experience. Making identity, security and privacy easy for customers provides a unique advantage over the competition.
Qosmos has announced new milestones in the detection of encrypted traffic and in protocol signature coverage. Qosmos latest software can accurately classify traffic encrypted with SSL/TLS (e.g., Google, Facebook, WhatsApp), P2P traffic (e.g., BitTorrent, MuTorrent, Vuze), and Skype, while preserving the privacy of communication content. These new classification techniques mean that traffic optimization, policy enforcement, and user experience are largely unaffected by encryption. In respect wit...
Fact: storage performance problems have only gotten more complicated, as applications not only have become largely virtualized, but also have moved to cloud-based infrastructures. Storage performance in virtualized environments isn’t just about IOPS anymore. Instead, you need to guarantee performance for individual VMs, helping applications maintain performance as the number of VMs continues to go up in real time. In his session at Cloud Expo, Dhiraj Sehgal, Product and Marketing at Tintri, wil...
19th Cloud Expo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterpri...
Enterprises have forever faced challenges surrounding the sharing of their intellectual property. Emerging cloud adoption has made it more compelling for enterprises to digitize their content, making them available over a wide variety of devices across the Internet. In his session at 19th Cloud Expo, Santosh Ahuja, Director of Architecture at Impiger Technologies, will introduce various mechanisms provided by cloud service providers today to manage and share digital content in a secure manner....
Smart Cities are here to stay, but for their promise to be delivered, the data they produce must not be put in new siloes. In his session at @ThingsExpo, Mathias Herberts, Co-founder and CTO of Cityzen Data, will deep dive into best practices that will ensure a successful smart city journey.
SYS-CON Events announced today that 910Telecom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and ...
To leverage Continuous Delivery, enterprises must consider impacts that span functional silos, as well as applications that touch older, slower moving components. Managing the many dependencies can cause slowdowns. See how to achieve continuous delivery in the enterprise.